Last $52.87 USD
Change Today +0.38 / 0.72%
Volume 1.4M
KITE On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

kite pharma inc (KITE) Snapshot

Open
$51.50
Previous Close
$52.49
Day High
$52.88
Day Low
$50.51
52 Week High
12/15/14 - $57.87
52 Week Low
07/16/14 - $21.00
Market Cap
2.2B
Average Volume 10 Days
1.2M
EPS TTM
--
Shares Outstanding
41.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for KITE PHARMA INC (KITE)

kite pharma inc (KITE) Related Bloomberg News

View More Bloomberg News

kite pharma inc (KITE) Related Businessweek News

No Related Businessweek News Found

kite pharma inc (KITE) Details

Kite Pharma, Inc. operates a clinical-stage biopharmaceutical company which focuses on the development and commercialization of novel cancer immunotherapy products. The company is developing a pipeline of eACT-based product candidates for the treatment of solid and hematological malignancies. Its lead product candidate includes KTE-C19, a chimeric antigen receptors-based engineered autologous cell therapy for the treatment of patients with relapsed/refractory diffuse large B cell lymphoma. The company is also developing T cell receptors-based therapies, which targets SSX2, NY-ESO-1, and MAGE antigens in various cancers. The company has collaboration agreement with the Surgery Branch of the National Cancer Institute. Kite Pharma, Inc. was founded in 2009 and is headquartered in Santa Monica, California.

36 Employees
Last Reported Date: 12/12/14
Founded in 2009

kite pharma inc (KITE) Top Compensated Officers

Founder, Executive Chairman, Chief Executive ...
Total Annual Compensation: $16.7K
Vice President of Translation Medicine
Total Annual Compensation: $325.0K
Consultant
Total Annual Compensation: $210.9K
Compensation as of Fiscal Year 2013.

kite pharma inc (KITE) Key Developments

Kite Pharma Seeks Acquisitions

Kite Pharma, Inc. (NasdaqGS:KITE) has filed a follow-on equity offering. Kite Pharma said, "We may also use a portion of the remaining net proceeds to in-license, acquire, or invest in complementary businesses, technologies, products or assets, including additional cancer immunotherapy product candidates."

Kite Pharma Receives Positive Opinion for Orphan Drug Designation in the European Union for KTE-C19, Kite's Lead Investigational Cancer Immunotherapy

Kite Pharma, Inc. announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion recommending KTE-C19 for designation as an orphan medicinal product for the treatment of diffuse large B cell lymphoma (DLBCL). KTE-C19 is an anti-CD19 CAR T cell therapy that involves genetically modifying a patient's T cells to express a CAR that is designed to target CD19, a protein expressed on the cell surface of B cell lymphomas and leukemias. The COMP, a committee of the EMA, adopts an opinion on the granting of orphan drug designation, after which the opinion is submitted to the European Commission for endorsement of the opinion.

Kite Pharma, Inc. Reports Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Kite Pharma, Inc. reported unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported a net loss attributable to common stockholders of $9.05 million or $0.24 per basic and diluted share, compared to net loss of $2.05 million or $0.37 per basic and diluted share a year ago. The company reported no revenues for the quarter. Operating loss was $9.10 million compared to $1.51 million a year ago. For the nine months, the company a net loss attributable to common stockholders of $30.64 million or $1.76 per basic and diluted share, compared to net loss of $4.85 million or $0.89 per basic and diluted share a year ago. Operating loss was $23.40 million compared to $4.03 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KITE:US $52.87 USD +0.38

KITE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KITE.
View Industry Companies
 

Industry Analysis

KITE

Industry Average

Valuation KITE Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 10.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KITE PHARMA INC, please visit www.kitepharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.